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ABSTRACT
The bZIP transcription factor NFIL3 (Nuclear
factor Interleukin 3 regulated, also known as E4
binding protein 4, E4BP4) regulates diverse
biological processes from circadian rhythm to
cellular viability. Recently, a host of novel roles
have been identified for NFIL3 in immunological
signal transduction, cancer, aging and
metabolism. Elucidating the signaling pathways
that are impacted by NFIL3 and the regulatory
mechanisms that it targets, inhibits or activates
will be critical for developing a clearer picture of
its physiological roles in disease and normal
processes. This review will discuss the recent
advances and emerging issues regarding NFIL3mediated transcriptional regulation of CEBPβ
and FOXO1 activated genes and signal
transduction.
Keywords: NFIL3, CEBPβ, Metabolism, Cancer,
Immunology.
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NFIL3 transcription factor is emerging as a key signaling component in a myriad of
cellular processes, such as: metabolism, nerve regeneration, immune development
and cancer.
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1. Introduction
The NFIL3 transcriptional repressor impacts many
cellular processes and is widely expressed in
normal murine and human tissues1-19. Often, NFIL3
action opposes that of transcriptional activators by
competing for access to target sites on
DNA2,7,13,15,20-22. NFIL3 is also commonly found
within the context of feedback regulatory circuits21.
The list of physiological roles for NFIL3 has
evolved tremendously over the last few years. In
addition to roles in circadian rhythm and B
cell/neuronal survival, NFIL3 is now implicated in
having far reaching activities from immunological
signal transduction to metabolism, aging and
cancer1-4,6,7,9-11,14,18,23,24. Here, we give an overview
of NFIL3 transcriptional regulatory circuits and
discuss emerging areas of NFIL3 research regarding
cancer and diabetes.
2. NFIL3 is a b-ZIP Transcriptional Regulator
NFIL3 was initially identified by its ability to bind
to and repress an E4 promoter sequence containing
an ATF consensus site25,26. Several years later,
NFIL3 was shown to bind to and activate the
transcription of an IL3 (Interleukin 3) promoter
sequence27.
Although most of the published
biological activities for NFIL3 involve its ability to
repress transcription, a handful of mammalian cell
culture studies as well as murine models indicate
that it may also activate transcription by novel
mechanisms27,28. The 462 amino acid sequence of
NFIL3 includes a b-ZIP domain spanning amino
acids 73-146 (Figure 1). The N-terminal portion of
this domain (amino acids 79-95) contains the basic
motif, which directly binds to DNA. The Cterminal portion of the b-ZIP domain (amino acids
99-106) contains an amphipathic leucine zipper
region, which is responsible for homo-dimerization
as well as hetero-dimerization interactions29. The
NFIL3 protein also has a unique transcriptional

repression domain that spans amino acids 299-363.
This repressor domain function is transferable,
since its fusion with the GAL4 DNA binding
domain leads to transcriptional repression in
reporter assays30.
The molecular mechanisms
employed by NFIL3 to repress transcription remain
to be fully elucidated. In cancer cells, NFIL3
physically associates with Histone deacetylase 2
(HDAC2) to repress the TRAIL (Tumor Necrosis
Factor Ligand Superfamily, Member 10), FAS (TNF
receptor superfamily member 6) and GADD45α
(Growth Arrest and DNA-damage-inducible, alpha)
genes2. In hepatocytes Nfil3 represses Fgf21
(Fibroblast Growth Factor 21) expression in a
histone methyltransferase G9a-dependent manner31.
Nfil3 represses many additional genes including
Period 2 (Per2), Arntl (Aryl Hydrocarbon Receptor
Nuclear Translocator-Like), Usp2-45 (Ubiquitinspecific protease 2-45), BGL-GS (also known as
BCL2-like 14), Cox2 (Cyclooxygenase 2), Runx2
(Runt-related transcription factor 2), Phex
(Phosphate Regulating Endopeptidase Homolog),
Ptgs2 (Prostaglandin-endoperoxide synthase 2, also
known as Cox2), Pgr (Progesterone receptor), and
Areg (amphiregulin), which are regulated in diverse
tissues ranging from pancreatic beta cells to
osteoblasts21,32-36.
3. Nfil3 Regulates Circadian Rhythm
The Nfil3 gene is expressed in a circadian manner
and encodes a regulator of circadian rhythm20,24,37-39.
Organisms ranging from bacteria to humans have
endogenous clocks or circadian rhythms that
integrate intrinsic and extrinsic cues to optimize
cellular growth and survival. These clocks are
regulated by complex, interlocked feedback loops
that are, in part, transcriptionally directed37. The
three most common circadian transcription factor
consensus sites are: 1) E/E’ box elements which are
activated by the Clock (circadian locomotor output
cycles kaput)/Bmal1 (brain and muscle ARNT-like
Figure 1: NFIL3 is a bZIP
Transcriptional
Repressor.
This schematic depicts the
overall domain structure of the
NFIL3 transcriptional repressor.
The
bZIP
and
minimal
repressor domains are indicated.
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protein 1) protein dimer 2) Rev-ErbA/ROR
elements (RREs) which are repressed by NR1D1
(Nuclear Receptor subfamily 1, group D, member 1,
also known as Rev/ErbA) and 3) D box elements
which are activated by the bZIP transcriptional
activator Dbp (D site albumin promoter binding
protein) and repressed by the bZIP transcriptional
repressor Nfil337. The mammalian circadian rhythm
is initiated by the basic helix loop helix (bHLH)PAS transcription factors Clock and Bmal1 which
form heterodimers that induce the transcription of
genes containing E box promoter elements
including Period genes (Per1, Per2 and Per3),
Cryptochrome genes (Cry1 and Cry2), Dbp, and
Rev/ErbA40,41.
Transcriptional programs that
activate genes in circadian rhythm are eventually
turned off by negative feedback mechanisms.
Period and Cry proteins form heterodimers to
ultimately hinder the induction of E box regulated
genes, Rev/ErbA repress RRE regulated genes
including the Bmal1 gene and NFIL3 represses D
box regulated genes40,41. The Nfil3 promoter
contains numerous RREs thereby facilitating its
circadian expression37. Mammalian Nfil3 shows
circadian expression in a large number of tissues
including suprachiasmatic nuclei, liver, kidney,
aorta, skeletal muscle, adrenal gland, and adipose
tissue42.
The mode of NFIL3 action on circadian
rhythm may be prototypical of its action on other
cellular processes. In circadian regulation, the
NFIL3 repressor acts in an anti-phase manner with
respect to the bZIP transcriptional activator DBP

(Figure 2)20,37. NFIL3 and DBP compete for access
to D box elements, exerting opposite effects on
target genes20. NFIL3 expression peaks when DBP
expression is at its lowest and vice versa (Figure
2A).
Therefore, D box regulated genes are
repressed when levels of NFIL3 are high and are
induced (by DBP) when NFIL3 levels are low
(Figure 2B). One of the most thought provoking
roles of Nfil3 action in the circadian rhythm is that
it has recently been shown to regulate period length
(the time to complete a circadian cycle, which is
normally 24 hours) in Rat1 fibroblast cells38.
Specifically, the loss of Nfil3 lengthens period
length whereas the overexpression of Nfil3 shortens
period length. Levels of Dbp have opposite effects
on period length38. Frequently, the circadian
rhythm is coupled to cellular processes such as cell
division and metabolism43-50.
It would be
informative to determine whether Rat1 cells grow
more quickly with exogenous Nfil3 expression as
one would predict with the altered circadian period
length. In addition, with a shorter period, are all
stages of the circadian rhythm and related cellular
processes affected equally by exogenous Nfil3 or
are certain aspects of this network differentially
impacted? Finally, it will be important to determine
whether NFIL3 affects period length in humans and
mice.
Another recent discovery links the circadian
function of Nfil3 to the development of Interleukin
17 producing CD4+ helper T (TH17) cells in the
immune system51. Th17 cells protect organisms
from bacterial and fungal infections on mucosal

Figure 2: NFIL3 regulates
D-box genes anti-phase to
DBP.
(A) Schematic shows how
NFIL3 and DBP peak at
different times during the
circadian rhythm.
(B) DBP binds to and
activates
D-box
genes,
whereas NFIL3 binds to and
represses D-box genes.
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membranes and are also associated with
inflammatory disease52,53. Nfil3 was found to
suppress TH17 cell development by binding to the
promoter of the orphan nuclear receptor Rorγt gene
and repressing transcription; Rorγt is required for
the specification of TH17 cells51,54. Interestingly,
Nfil3 was found to be highly expressed at night in
mice whereas Rorγt was found highly expressed
during the day51.
Accordingly, TH17 cell
frequencies were significantly higher during the day
in with-type mice51. This diurnal difference in
TH17 cells was abrogated in Nfil3 -/- mice51. This
study is an exciting example that links the circadian
and immunological functions of Nfil3. Overall,
these emerging areas of Nfil3 regulated circadian
processes highlight not only the basic mechanistic
insights of its action, but also important connections
within a broader cellular context.
4. Light and Nutrient Availability Regulate
NFIL3 Expression
The circadian rhythm has been shown to be coupled
to metabolic processes in a number of tissues to
coordinate behaviors such as rest and locomotion
with cues such as light and nutrient availability55-57.
As a circadian regulator, Nfil3 impacts metabolism
by being part of the cell intrinsic oscillator20-37. In
addition to cell intrinsic regulation, Nfil3 stands out
as a circadian component that is induced by
environmental cues such as light and feeding,
thereby enabling cells to integrate internal and
external cues24,58. The chick pineal gland is used as
a model system to study circadian oscillations in
response to light due to the fact that chick
pinealocytes possess a circadian oscillator and a
photo-transduction pathway for light entrainment57.
By exposing young chicks to varying light/dark
cycles, it was found that NFIL3 had a role in light
entrainment. Under normal conditions, NFIL3
expression in the chicken pineal gland peaks at
early subjective night32. NFIL3 protein represses the
expression of the PERIOD2 (PER2) gene, which is
expressed in an anti-phase manner to NFIL3 and
peaks in the morning32. Light exposure during early
subjective night leads to an induction in NFIL3
gene expression and a delay in the expression of
PER2 the next morning.
Sterol Regulatory
Element-Binding Protein (SREBP) is a transcription
factor that induces NFIL3 expression in the chick
pineal gland upon light exposure during early
www.discoveriesjournals.org

subjective night to ultimately cause a delay in
PER2 expression the next morning58. In sum,
studies in chicks have revealed a role for Nfil3 in
shifting the expression of PER2 to a later time in
response to light. It will be interesting to determine
whether related mechanisms are employed in
mammals.
Insulin and feeding are additional
environmental cues that induce the expression of
Nfil3. Feeding potently induces the expression of
Nfil3 in the mouse liver, whereas fasting has the
opposite effect24. Furthermore, insulin induces
Nfil3 expression in Hepa1C1C-7 cells in a PI3K
dependent manner.
One of the Nfil3 repressed
genes in the liver is Fgf21 encodes a potent antidiabetic and triglyceride lowering hormone24.
During fasting, Fgf21 is critical for lipolysis,
gluconeogenesis, and ketogenesis. Mechanistically,
Nfil3 physically associates with D box elements on
the Fgf21 promoter in hepatocytes to repress
transcription in a manner that depends on the
histone methyltransferase G9a31.
Thus, upon
nutrient availability, Nfil3 action may lead to an
epigenetic shift to maximize metabolism and
biogenesis.
Additionally,
Ubiquitin-specific
protease 2-45 (Usp2-45) was identified as another
Nfil3 repressed gene in hepatocytes34. Usp2-45
encodes
a
deubiquitinase
that
regulates
gluconeogenesis and glucose metabolism in the
liver34. Under starvation conditions, Peroxisome
proliferator-activated receptor-gamma coactivator
alpha (Pgc1α) and Peroxisome proliferatoractivated receptor-gamma coactivator beta (Pgc1β)
along with Hepatocyte nuclear factor 4 (Hnf4)
activate the transcription of Usp2-45, whereas Nfil3
strongly represses this gene under fed conditions.
The ability of Pgc1α to induce Usp2-45 is strongly
enhanced when cells are transduced with Nfil3
shRNA (to diminish Nfil3 expression)34.
In
summary, under fed conditions, Nfil3 expression is
induced, leading to the repression of a number of
genes (Fgf21 and Usp2-45) to shift metabolic
processes. Taken as a whole, the ability of Nfil3 to
regulate metabolism is becoming increasingly
evident and suggests that it may have a role in
diabetes.
5. NFIL3 in Development and Cell Fate
A number of breakthrough studies have revealed
that NFIL3 not only regulates oscillatory

4

Emerging Cellular Roles for bZIP Factor NFIL3

mechanisms, but also has tremendous impacts on
developmental processes.
Some of the most
significant advances relating to NFIL3 biology were
recently made in the field of immunology. Nfil3
was recently found to be essentially required for
Natural Killer (NK) cell development and function.
Nfil3 has also been found to impact B-cell, T-cell,
dendritic cell and macrophage responses.
In
addition to roles in immunological development,
NFIL3 has also been recently found to significantly
impact heart development and aging in numerous
model organisms.
These studies highlight
completely novel roles for NFIL3 in the field of
developmental biology.
5.1 Immunological Role of Nfil3
Recently it has become clear that Nfil3 has
significant
contributions
to
immunological
59
development and function . Initially shown to be
critical for natural killer cell (NK) development,
Nfil3 is also required for efficient Immunoglobulin
E (IgE) class switching and for the attenuation of
numerous
inflammatory
responses1,6,12,14,23.
Arguably, the most striking immunological
phenotype for mice that lack Nfil3 is the dramatic
loss of mature NK cells14,23. Mice that were nfil3 -/had normal B and T cell development, but showed
defective development, maturation and function of
NK cells. A 35 fold reduction of splenic NK cells
was observed in nfil3 -/- mice. The few NK cells
that did develop in nfil3 -/- mice were functionally
defective in the ability to stimulate IFNγ (Interferon Gamma) upon IL2 (Interleukin 2) plus
IL12 (Interleukin 12) stimulation. Of note, Nfil3
was recently found to be dispensable for the
development of TRAIL+ NK cells60. Therefore,
Nfil3 is not required for the development of all NK
lineages. NK cells are best known for their
cytotoxicity to stressed cells such as those that are
virally infected or cancerous. NK cells also have
important roles in immunological modulation. For
example, NK cell action can dampen CD8+ T cell
immune response to viruses, leading to chronic
infections as seen with HIV and Hepatitis B61. A
unique set of human decidual natural killer cells
have recently been shown to express NFIL3 and
have important roles in tissue remodeling,
neoangiogenesis, and immune modulation to
prevent fetal rejection62. These studies highlight the

www.discoveriesjournals.org

central role of Nfil3 in NK development and
suggest that it has an impact in defending organisms
against viral infections.
Aside from NK phenotype, Nfil3 also has
roles in B cell, dendritic cell, T cell and
macrophage-derived immunological responses59. In
murine B cells, Nfil3 is required for IgE class
switching and thus generation of IgE production,
involved in allergic response11,12. Nfil3 binds to the
Iε exon promoter, which is thought to promote the
production of IgE12. Mice that are nfil3 -/- also
lack mature CD8α+ dendritic cells that are crucial
for antigen presentation and cross priming CD8+ T
cells against cell presented antigens10. Other Nfil3
immunological events appear to involve potential
feedback loops where Nfil3 may have roles in
attenuating inflammation by either inhibiting the
production of cytokines such as IL12 in
macrophages or IL5 (Interleukin 5) and IL13
(Interleukin 13) in helper Th2 cells6,9,10,63. Nfil3
also augments the expression of the antiinflammatory cytokine IL10 (Interleukin 10) in
helper T cells (Th1 and Th2)28. Interestingly,
NFIL3 is highly expressed in T cells that were
isolated from patients with systemic lupus
erythematosus (SLE); studies using human T cells
showed that exogenous NFIL3 hindered T-cell
activation and self-reactivity64. Overall, nfil3-/mice are immunologically deficient with an almost
complete absence of NK function, highly defective
IgE production and defective antigen presentation
from CD8+ T cells. These mice also lack important
immunological regulatory mechanisms to hinder
inflammation such as the production of IL10.
5.2 NFIL3 is Involved in Heart Development and
Aging
The ability of NFIL3 to influence heart
development and function has recently emerged.
In Drosophila melanogaster, transcriptome analysis
revealed that aged hearts express more of the
NFIL3 homolog Vrille than younger hearts5. Aging
in Drosophila heart tissue is characterized by an
increase in heart period (HP; average time between
successive end-diastolic positions). Vrille overexpression led to dilation of the heart. The loss of
Vrille dramatically influenced HP: normal flies
show a 55% increase in HP between ages 10 and 45
days, whereas Vrille loss of function flies only
showed a 6% increase5. A significant number of

5

Emerging Cellular Roles for bZIP Factor NFIL3

the putative Vrille target genes, based on the
presence of consensus sites and loss of expression
in aged flies, were involved in mitochondrial
function. Therefore, Vrille may hinder mitochondrial function to promote heart aging.
NFIL3 has also recently been investigated
as having a role in heart development and disease in
zebra fish (Danio rerio) and rats (Rattus
norvegicus). Specifically, loss-of-function analyses
of the NFIL3 homolog in zebra fish indicate that it
is important for normal heart development65. RNAi
targeting of the zebra fish NFIL3 homolog led to
malformed looping of the embryonic heart tube
which occluded blood flow and retarded cardiac
growth65. This same study showed that the overexpression of Nfil3 in rat embryonic fibroblasts
induced the expression of survival genes such as
Igf1 (Insulin-like growth factor 1), Igf1r (Insulinlike growth factor 1 receptor) and Bcl2 (B-cell
lymphoma 2) and hindered caspase 3 induction
preventing apoptosis65. Yet another study showed
that infarct volume and fibrosis were higher in
mouse models subjected to ischemia/reperfusion
during the time of day when Nfil3 was at its lowest,
suggesting a survival role for Nfil3 in the heart66.
Altogether, Nfil3 is emerging as an important
cardiac signaling factor that on the one hand
promotes aging and on the other hinders cell death.
6. NFIL3 Influences Cellular Survival
Programmed cell death is utilized throughout
development and during homeostatic programs in
tissues. For example, 50% of neurons undergo
apoptosis during development67.
NFIL3 has
emerged as a survival factor that hinders the
induction of apoptosis in numerous settings from Bcells to motor neurons2,19,68. Nfil3 was first shown
to hinder apoptosis in murine pro-B lymphocytes
which normally require the addition of IL3
(Interleukin 3) to the media for cellular survival19.
IL3 binds to its cognate receptor to activate Ras as
well as (B-cell lymphoma-extra large) Bcl-XL
thereby mediating survival18. The removal of IL3
leads to cell death, which can be rescued by the
exogenous expression of anti-apoptotic factors such
as Bcl2, Bcl-XL and c-Myc18. Nfil3 is thought to
have an important role in mediating the IL3 survival
signal19. Nfil3 transcription is strongly induced by
IL3 in a mechanism that involves the Ras pathway
(activates GATA1 which binds to and activates
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NFIL3) and the Phosphatidylinositol 3 kinase
(PI3K) pathway in pro-B cells18,19,69,70. Conversely,
IL3 removal leads to a rapid loss in Nfil3
expression19. Exogenous Nfil3 expression strongly
hinders IL3 deprivation induced cell death in
FL5.12 murine pro-B lymphocytes19. In BAF-3
pro-B lymphocytes, Nfil3 was shown to rescue
viability upon IL3 deprivation18,19, but not upon
Interleukin 6 (IL6) deprivation71. Aside from the
interleukin utilized in these rescue experiments (IL3
versus IL6), another key difference was that CD8
was exogenously expressed in the successful rescue
experiments, which may have promoted the Nfil3
survival signal18,19,71. Loss-of-function experiments
also indicate that Nfil3 is a survival factor in pro-B
lymphocytes.
Specifically, the expression of
dominant negative NFIL3 (contains a mutated basic
region that fails to bind DNA, but forms
heterodimers with wild-type NFIL3) antagonized
the ability of IL3 to promote cellular survival18.
Higher amounts of IL3 were required to maintain
Baf-3 pro-B cells in the presence of dominantnegative-NFIL3. Thus, numerous studies indicate
that Nfil3 promotes IL3 mediated survival.
In addition to pro-B cells, Nfil3 also
impacts the survival of motor neurons. During
embryonic development more than half of the
motor neurons produced undergo programmed cell
death67. Nfil3 is highly expressed in vivo in
embryonic rat and chicken motor neurons that
survive developmental pruning68. Gain-of-function
experiments showed that exogenous Nfil3 hindered
motor neuron cell death upon trophic factor
deprivation68. In addition to this, Fas ligand (FasL)
induced motor neuron death was completely
blocked by exogenous Nfil368. Gain-of-function
experiments were also performed with chicken
embryos. Specifically, E2.5 embryos were
electroporated with NFIL3, which led to the
survival of 45% more motor neurons68. These
results highlight the importance of NFIL3 in
neuronal programmed cell death. It will be exciting
to determine whether NFIL3 impacts apoptosis
during additional developmental processes, and
particularly those that involve pruning.
Although many studies have shown an antiapoptotic affect for Nfil3, this may not be the case
for all physiologic settings. In glucocorticoid (GC)
signal transduction, Nfil3 may induce cell death3,72,.
The glucocorticoid receptor (GR) is normally
regulated by a negative feedback mechanism upon
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activation; the GR mRNA and protein are downregulated after GC addition3. However, in certain
GC treated murine leukemic T cell lines, GR
activation is not attenuated leading to
glucocorticoid induced cell death3,72,73. The Nfil3
gene is induced under these conditions and is
thought to be part of the mechanism that activates
apoptosis. The knockdown of Nfil3 by RNA
interference in CTLL-2 cytotoxic T lymphocyte
cells partially rescued GC induced apoptosis3.
Thus, Nfil3 regulates cell death in a context
dependent manner.
7. NFIL3 in Cancer
In line with its ability to hinder cell death, NFIL3
has emerged as a novel survival factor in cancer.
NFIL3 was found highly expressed in a number of
poor prognosis cancers such as glioblastoma
multiforme and basal like breast cancer. NFIL3
expression in breast cancer was found strikingly
associated with poor prognosis by Kaplan Meier
survival analysis2. Functionally, NFIL3 binds to and
represses pro-apoptotic genes such as TRAIL to
hinder the induction of apoptosis in cancer cells.
The diminishment of NFIL3 by RNA interference
led to cell death in the BT549, MDA-MB-468 and
U87MG cancer cell lines2. Conversely, NFIL3
overexpression hindered H2O2 induced apoptosis in
these same cancer cell lines2. On a mechanistic
level, NFIL3 acted at least in part to physically
block FOXO1 (Forkhead box O1) recruitment to
apoptosis inducing genes by binding to promoter
elements that have adjacent FOXO and NFIL3
consensus sites2. It is important to mention that
NFIL3 did not block FOXO1 recruitment to all
target genes, but just to a subset of genes involved
in tumor suppression2. This data suggested that
nuclear FOXO1 may still trans-activate non-NFIL3
target genes and that it may even promote cancer in
this setting. Therefore, NFIL3 may physically
block the ability of FOXO1 to induce cell death
genes, so that FOXO1 can direct pro-oncogenic
transcriptional programs without killing cells. At
least two other recent studies have also found that
nuclear FOXO may have pro-oncogenic roles.
First, FOXO1 was found to be mutated to a
presumably activated form in 8.6% of DLBCL
(Diffuse large non-B-cell lymphoma); the FOXO1
mutations in this setting were strikingly associated
with poor prognosis74. The FOXO1 mutations that
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were discovered in DLBCL clustered to two regions
within the FOXO1 protein. One of the regions alters
residues in the DNA binding domain, whereas the
other affected region is proximal to Threonine 24
(T24), which is phosphorylated by AKT on the
PI3K pathway74,75. T24 phosphorylation on FOXO1
promotes its interaction with the scaffolding protein
14-3-3, leading to cytoplasmic localization75.
Interestingly, the M1L, R19Q, R21C, and T24
mutant forms of FOXO1 (found in DLBCL) failed
to be phosphorylated on T24, failed to interact with
14-3-3 and were retained in the nucleus to
presumably drive gene expression, suggesting a
pro-oncogenic role for nuclear FOXO1 in this
setting74. FOXO factors were also discovered to
promote the development of AML in an MLL-AF9
murine model for leukemia76. In this model the loss
of all three FOXO factors led to a significantly
longer latency for the development of AML with a
16 fold reduction in leukemia initiating cells. It will
be critical to determine whether NFIL3 is required
in DLBCLs that contain activated FOXO1 and the
MLL-AF9 cancers in order to block the activation
of cell death by FOXO factors. The full spectrum
of NFIL3 regulated transcriptional programs in
cancer have yet to be elucidated. Most likely there
will only be partial overlap with its output and the
FOXO-induced cell death genes.
In addition to its ability to block FOXO
recruitment to cell death genes, NFIL3 may also
block the recruitment of Proline Acid Rich (PAR)
transcription factors to pro-apoptotic genes in colon
cancer77. NFIL3 was found to repress the proapoptotic, BH3-only gene BGL-GS (also known as
BCL2-like 14) in colon cancer cells77. The BCL-GS
protein binds to Bcl-XL to promote apoptosis77. In
contrast, the PAR proteins: DBP, TEF (Thyrotroph
Embryonic Factor) and HLF (Hepatic Leukemia
Factor) can induce a BCL-GS promoter-driven
reporter gene in cancer cell lines77. The BGL-GS
gene was repressed by NFIL3 and activated by PAR
bZIP factors by regulation through the same
consensus site. This study also showed that TEF
binding to the endogenous BCL-GS gene was
induced by cisplatin and etoposide treatment77.
Thus, NFIL3 may block the recruitment of bZIP
transcriptional activators to pro-apoptotic genes to
potentially hinder chemotherapeutic response. In
addition to colon cancer, NFIL3 may have a role in
esophageal cancer as irradiation of esophageal
cancer cell lines leads to a loss in NFIL3
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expression78. Delineating the full breadth of NFIL3
directed transcriptional programs such as those that
counter FOXO and PAR transcription factors will
be essential for understanding its contribution to
cancer.
8. Nfil3 in Neuronal Regeneration
Neuronal regeneration in dorsal root ganglion cells
is driven by transcriptional programs that include
Nfil3-mediated
repression
of
regeneration
7,13
associated genes . Nfil3 is overexpressed in
regenerating DRG neurons in vivo, but has a
negative
impact
on
neurite
outgrowth13.
Knockdown of Nfil3 by siRNA and expression of
dominant negative NFIL3 induced neurite
outgrowth in primary adult rat DRG neurons13. The
ability of NFIL3 to compete for access to consensus
promoter sequences is becoming a recurring theme
for its action in signaling circuits. In neurons, Nfil3
appears to compete for access to sites shared with
cAMP-response element binding protein (CREB)
and CCAAT/Enhancer Binding Protein (CEBPβ) to
regulate transcriptional programs during neuronal
regeneration7,13. Nfil3 resides within a feedback
loop
that
starts
with
cAMP-induced
phosphorylation of CREB. Next, phosphorylated
CREB activates Nfil3 expression, which represses
CREB target genes as well as Cebpβ targets by
competing with transcriptional activators for access

to target genes. At the same time, Nfil3 binds to its
own promoter to repress its own expression7,13.
This creates a highly regulated pulse of cAMP
signaling in neurons. Of note, Nfil3 expression was
specifically found in neurons that were able to
regenerate, suggesting that it had a role in this
process13. The experimental evidence points to a
role for Nfil3 as a component that may promote a
greater signaling sensitivity by being an attenuating
factor. In sum, CREB activates transcriptional
programs including the Nfil3 repressor which acts
to attenuate the initial signal. In this manner, only a
pulse of signal occurs instead of a sustained signal.
It will be exciting to determine whether this type of
feedback circuitry comes into play in additional
Nfil3-mediated signaling pathways.
9. Nfil3 in Osteoblast Signal Transduction
Nfil3 was identified as a target of parathyroid
hormone (PTH) in murine osteoblasts by
representational display analysis15. The addition of
PTH to primary mouse osteoblasts rapidly induced
Nfil3 transcription in a manner that did not require
new protein synthesis15. PTH treatment of
osteoblasts induced Nfil3 binding to DNA probes
that contained Nfil3 binding sites; this binding
could be specifically super-shifted by NFIL3
antibody15. However, NFIL3 antibody was unable
to super-shift the all PTH induced complexes that

Figure 3. Emerging Cellular
Roles for NFIL3.
Metabolism, nerve regeneration, cancer development
and immunological development have recently been
found to be impacted by
NFIL3.
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bound to the Nfil3 consensus site. Querying
TRANSFAC (TRANScription FACtor database)
revealed that the Nfil3 DNA binding element
closely resembled the Cebpβ binding site and it was
known that PTH also induced Cebpβ expression.
Further experiments revealed that CEBPβ antibody
could super-shift the additional PTH-induced
complexes15. A model was put forth in which Nfil3
and Cebpβ compete for binding sites to repress and
activate targets respectively in response to PTH.
The signaling downstream of PTH includes
adenylate cyclase and PKA (Protein kinase A),
which were shown to be required for the ability of
PTH to activate Nfil3 expression21. In addition,
another activator of PKA, prostaglandin E2 (PGE2)
was also able to activate Nfil3 expression.
Forskolin, a direct activator of adenylate cyclase
could
also
induce
Nfil3
expression.
Cyclooxygenase 2 (Cox2) is thought be one of the
Nfil3 repressed genes downstream of PTH in mouse
osteoblasts21. Additional Nfil3 targets in murine
osteoblasts include Runx2, Osterix, and Phex21,35,36.
These studies provide important clues about Nfil3
signal transduction in osteoblasts and place its
action downstream of PKA.
10. NFIL3-CEBPβ
β Antagonism: A Recurring
Theme
The ability of Nfil3 to compete for DNA access
with the transcriptional activator Cebpβ is
becoming a commonly observed phenomenon.
Nfil3 was found to repress Cebpβ target genes such
as Ptgs2, Pgr and Areg in rat ovaries. Chromatin
immunoprecipitation analysis with CEBPβ and
NFIL3 specific antibodies revealed that hCG
treatment led to Cebpβ promoter recruitment at 6
hours post-treatment, which was followed by
increasing levels of Nfil3 promoter recruitment
(between hours 6-12 post hCG treatment)
accompanied by transcriptional repression of target
genes and diminishing Cebpβ recruitment8. The
recruitment of these factors to target sequences was
further confirmed by EMSA8. In addition to a role
in ovulation, NFIL3 was also found to hinder
CEBPβ recruitment to Human Hepatitis B viral
genes22. The overexpression of NFIL3 led to a loss
in hepatitis B virion production22. In sum, the
ability of NFIL3 to hinder CEBPβ promoter
recruitment may have a tremendous impact on
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many cellular signaling circuits and introduces a
new recurring paradigm for NFIL3 action.
11. Conclusions and Future Directions
NFIL3 is emerging as a key signaling component in
a myriad of cellular processes including
metabolism,
nerve
regeneration,
immune
development and cancer (Figure 3). NFIL3
commonly antagonizes the recruitment of
transcriptional activators to attenuate a signal. In
addition to the well characterized ability of NFIL3
to act in an anti-phase manner to DBP with
reference to the circadian rhythm, NFIL3 is
recurrently found to act in an antagonistic manner
to CEBPβ7,13,15,20. Nfil3 hinders the recruitment of
Cebpβ to target genes in motor neurons and
osteoblasts. It also appears to hinder CEBPβ
recruitment during virus production22.
Very
recently, NFIL3 has emerged as a novel factor that
might promote human diseases such as diabetes and
cancer. Strikingly, the expression of NFIL3 is
significantly associated with poor outcome in
cancer2. In cancer cells, NFIL3 was found to block
FOXO1 access to cell death genes, potentially
allowing FOXO1 to drive pro-oncogenic programs,
a true paradigm shift for the PI3K pathway2. Many
of the recent insights into NFIL3 biology have been
gleaned from cell-based studies. New frontiers for
NFIL3 studies will include more in depth in vivo
models as well as trying to place NFIL3 into
complex signaling cascades. Future research may
reveal novel factors for NFIL3 to antagonize as well
as mechanisms by which this factor may actually
induce transcription as in the case of the IL3 gene.
Finally, the regulation of NFIL3 will be an exciting
new frontier for future research and will have broad
implications for cellular processes discussed in this
review as well as human diseases such as cancer
and diabetes.
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(T24); cAMP-response element binding protein
(CREB); CCAAT/Enhancer Binding Protein beta
(CEBPβ); Parathyroid Hormone (PTH); TRANScription
FACtor database (TRANSFAC); Protein kinase A
(PKA); Prostaglandin E2 (PGE2); Cyclooxygenase 2
(Cox2); Runt-related transcription factor 2 (Runx2);
Phosphate Regulating Endopeptidase Homolog (Phex);
Prostaglandin-endoperoxide synthase 2 (Ptgs2; also
known as Cox2); Progesterone receptor (Pgr);
Amphiregulin (Areg)
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